Interestingly, in colorectal cancer and melanoma, enhanced anti-PD-1 efficacy could be achieved by depletion of METTL3 and METTL14, potentially via increased CD8+ T-cell infiltration and tumor killing function [288]. This evidence concerns the gene METTL3 and colorectal cancer.